Study of the Effects of Oral AT1001 in Patients with Fabry Disease

• Research type

  Research Study

• Full title

  A Double-Blind, Ramdomized, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients with Fabry disease and AT1001- responsive GLA Mutations

• IRAS ID

  33587

• Sponsor organisation

  Amicus Therapeutics, Inc.

• Eudract number

  2009-013459-31

• Clinicaltrials.gov Identifier

  NCT00925301

• Research summary

  N/A

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  09/H0803/139

• Date of REC Opinion

  10 Dec 2009

• REC opinion

  Further Information Favourable Opinion